Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 12Active not recruiting 10Terminated 4Recruiting 3Withdrawn 1Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4

Conditions

Melanoma 40Carcinoma, Non-Small-Cell Lung 35Carcinoma, Renal Cell 26Neoplasm Metastasis 19Lung Neoplasms 18Carcinoma, Hepatocellular 15Squamous Cell Carcinoma of Head and Neck 11Colorectal Neoplasms 11Pancreatic Neoplasms 10Neoplasms 9Carcinoma, Transitional Cell 9Multiple Myeloma 8Urinary Bladder Neoplasms 7Small Cell Lung Carcinoma 7Head and Neck Neoplasms 7Breast Neoplasms 7Triple Negative Breast Neoplasms 6Ovarian Neoplasms 6Hodgkin Disease 6Advanced Cancer 6Myelodysplastic Syndromes 5Hematologic Neoplasms 5Brain Neoplasms 5Skin Neoplasms 4Recurrence 4Lymphoma 4Kidney Neoplasms 4Glioblastoma 4Fallopian Tube Neoplasms 4Uveal Melanoma 3

Interventions

Temozolomide 52Radiotherapy 24Bevacizumab 23Radiation 10Magnetic Resonance Spectroscopy 7Lomustine 7Carmustine 7Radiosurgery 6Surgical Procedures, Operative 5Irinotecan 5Radiotherapy, Intensity-Modulated 4Nivolumab 4Ipilimumab 4Erlotinib Hydrochloride 4Cilengitide 4Aminolevulinic Acid 4vocimagene amiretrorepvec 3vitespin 3sargramostim 3poly ICLC 3pembrolizumab 3fluoromisonidazole 3carmustine, poliferprosan 20 drug combination 3Vorinostat 3TPI-287 3O(6)-benzylguanine 3Granulocyte-Macrophage Colony-Stimulating Factor 3Flucytosine 3Dynamic Contrast Enhanced Magnetic Resonance Imaging 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Glioblastoma × Nivolumab × Clear all
NCT03430791 2023-02-02

Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma

Baptist Health South Florida

Phase 2 Terminated
5 enrolled 10 charts
CNS

Glioblastoma

NCT03422094 2021-10-27

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Washington University School of Medicine

Phase 1 Terminated
3 enrolled
CNS

Glioblastoma

NCT03707457 2020-07-02

Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Terminated
3 enrolled
CNS

Glioblastoma

NCT02648633 2017-05-31

Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma

University of Virginia

Phase 1 Terminated
4 enrolled
CNS

Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡